Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19237449 | RAPID ISOLATION, CULTIVATION METHODS AND UTILITIES OF TRUFFLE FUNGI | June 2025 | December 2025 | Allow | 6 | 2 | 1 | Yes | No |
| 18831490 | PREBIOTIC AND PROBIOTIC FORMULATION CONTAINING ACID AND HEAT RESISTANT BACTERIA | February 2025 | March 2026 | Abandon | 13 | 1 | 0 | No | No |
| 18621769 | RAPID ISOLATION, CULTIVATION METHODS AND UTILITIES OF TRUFFLE FUNGI | March 2024 | May 2025 | Allow | 13 | 3 | 1 | Yes | No |
| 18618941 | PROBIOTIC SUPPLEMENT FOR METABOLIC HEALTH | March 2024 | October 2025 | Allow | 18 | 1 | 1 | No | No |
| 18425174 | NOVEL SIALIDASES AND USES THEREOF | January 2024 | June 2025 | Abandon | 16 | 1 | 1 | No | No |
| 18408667 | POSTBIOTIC PREPARATION FOR PELVIC FLOOR MUSCLE REHABILITATION AND PREPARATION METHOD AND APPLICATION THEREOF | January 2024 | December 2024 | Allow | 11 | 1 | 0 | Yes | No |
| 18445613 | Probiotic Formulation for Intestinal Dysbiosis | November 2023 | April 2025 | Abandon | 17 | 2 | 0 | Yes | No |
| 18389115 | DETECTION OF MYCOBACTERIUM ON GROWTH MEDIA | November 2023 | February 2026 | Allow | 27 | 1 | 0 | No | No |
| 18495757 | METHODS FOR PROMOTING INTESTINAL HEALTH AND FOR ENHANCING ANTIOXIDATION USING PREBIOTIC COMPOSITION | October 2023 | May 2024 | Allow | 7 | 0 | 0 | No | No |
| 18372656 | STRAINS OF LACTOBACILLUS DELBRUECKII WHICH INHIBIT PORPHYROMONAS GINGIVALIS | September 2023 | June 2025 | Allow | 21 | 2 | 1 | No | No |
| 18459983 | Methods for Treating a Health Condition with Probiotics | September 2023 | August 2025 | Allow | 23 | 2 | 0 | Yes | No |
| 18352485 | COMBINATION PRODUCT FOR PROPHYLAXIS AND TREATMENT OF IRRITABLE BOWEL SYNDROME | July 2023 | January 2024 | Allow | 6 | 3 | 0 | No | Yes |
| 18350557 | IMMUNOSTIMULATORY BACTERIA FOR THE TREATMENT OF CANCER | July 2023 | December 2025 | Allow | 29 | 3 | 1 | No | No |
| 18219731 | CULTURE METHOD FOR HIGH-CONCENTRATION HAEMATOCOCCUS PLUVIALIS | July 2023 | March 2025 | Abandon | 20 | 2 | 0 | Yes | No |
| 18217140 | COMPOSITION FOR TREATING IRRITABLE BOWEL SYNDROME | June 2023 | December 2023 | Allow | 5 | 1 | 0 | No | No |
| 18137752 | DIETARY SUPPLEMENT | April 2023 | May 2025 | Allow | 24 | 2 | 1 | No | No |
| 18299197 | COMPOSITION COMPRISING LACTOBACILLUS PLANTARUM FOR PREVENTING AND/OR TREATING MENTAL ILLNESS | April 2023 | September 2024 | Abandon | 17 | 1 | 0 | No | No |
| 18132565 | COMPOSITION FOR PROMOTING ABSORPTION OF PHYTOCHEMICALS | April 2023 | October 2025 | Abandon | 30 | 2 | 1 | No | No |
| 18025944 | PROBIOTIC COMPOSITIONS FOR THE TREATMENT OF ACNE | March 2023 | January 2026 | Allow | 35 | 2 | 0 | No | No |
| 18181301 | RECOMBINANT BACTERIUM WITH A HIGH PHA YIELD AND THE CONSTRUCTION METHOD THEREOF | March 2023 | April 2024 | Allow | 14 | 2 | 1 | No | No |
| 18115933 | COMPOSITION FOR TREATING IRRITABLE BOWEL SYNDROME | March 2023 | December 2023 | Allow | 9 | 2 | 1 | No | No |
| 18023287 | METHOD AND SYSTEM FOR STUDYING OBJECTS, IN PARTICULAR BIOLOGICAL CELLS | February 2023 | January 2026 | Abandon | 35 | 0 | 1 | No | No |
| 18147224 | MICROBIOME MARKERS AND THERAPIES FOR AUTISM SPECTRUM DISORDERS | December 2022 | May 2024 | Allow | 16 | 2 | 0 | Yes | No |
| 18146209 | TOMATO PATHOGENIC FUNGUS DETECTING APPARATUS AND DETECTING METHOD USING SAME | December 2022 | April 2024 | Allow | 16 | 2 | 0 | Yes | No |
| 17957633 | CELLULOSIC ENZYME RECYCLING FROM SEPARATION OF SACCHARIFIED BIOMASS | September 2022 | January 2024 | Allow | 16 | 1 | 0 | No | No |
| 17907617 | MEDIUM FOR BACILLUS CEREUS GROUP DETECTION | September 2022 | January 2026 | Allow | 39 | 2 | 0 | No | No |
| 17953610 | POSTBIOTIC COMPOSITIONS AND RELATED METHODS FOR AGRICULTURE | September 2022 | October 2025 | Abandon | 37 | 1 | 0 | No | No |
| 17907523 | DETERMINISTIC LATERAL DISPLACEMENT ARRAY WITH A SINGLE COLUMN OF BUMPING OBSTACLES | September 2022 | October 2025 | Abandon | 37 | 0 | 1 | No | No |
| 17950391 | ALGAL BOTANICAL EXTRACTS RICH IN EICOSAPENTAENOIC ACID AS TRI/DIGLYCERIDE CONJUGATE | September 2022 | November 2025 | Abandon | 38 | 2 | 0 | No | No |
| 17941915 | Novel Microbial Biomass Based Feed Products | September 2022 | June 2025 | Abandon | 34 | 2 | 0 | No | No |
| 17902330 | LACTOCOCCUS LACTIS SUBSP. LACTIS A32, DERIVED PRODUCT AND USE THEREOF | September 2022 | May 2023 | Allow | 8 | 1 | 0 | No | No |
| 17818977 | METHOD OF IMPROVING MEMORY AND LEARNING ABILITY | August 2022 | May 2023 | Allow | 9 | 1 | 0 | No | No |
| 17885189 | METHOD FOR ALLEVIATING ATOPIC DERMATITIS | August 2022 | July 2023 | Allow | 11 | 1 | 0 | No | No |
| 17795764 | COMPOSITION OF MICROORGANISMS FOR BREEDING INSECTS | July 2022 | September 2025 | Abandon | 37 | 1 | 1 | No | No |
| 17815530 | MICROORGANISMS CONVERTING INOSITOL TO BUTYRATE | July 2022 | October 2025 | Abandon | 39 | 0 | 1 | No | No |
| 17863964 | COENZYME Q10 FORMULATIONS IN THE TREATMENT AND PREVENTION OF EPIDERMOLYSIS BULLOSA | July 2022 | January 2026 | Allow | 42 | 3 | 1 | No | No |
| 17843087 | COMBINATION PRODUCT FOR PROPHYLAXIS AND TREATMENT OF IRRITABLE BOWEL SYNDROME | June 2022 | January 2024 | Abandon | 19 | 1 | 0 | No | No |
| 17807077 | Biopesticide composition for use in preventing or minimizing plant disease | June 2022 | September 2025 | Abandon | 39 | 0 | 1 | No | No |
| 17743469 | METHOD FOR MANUFACTURING BACTERIALLY INDUCED CRYSTAL PARTICLE | May 2022 | April 2024 | Allow | 23 | 2 | 0 | No | No |
| 17737170 | Microbial Contamination Control in Bioprocessing | May 2022 | March 2025 | Allow | 34 | 1 | 1 | No | No |
| 17734621 | METHOD FOR CULTURING UNICELLULAR RED ALGAE (URA) WITH MILK PERMEATE | May 2022 | February 2024 | Allow | 21 | 1 | 0 | No | No |
| 17772813 | STRAIN WITH IMPROVED AROMATIC AMINO ACID PRODUCTION CAPACITY BY YEEO GENE INACTIVATION | April 2022 | June 2025 | Abandon | 37 | 1 | 1 | No | No |
| 17755101 | COMPOSITION FOR THE CARDIOVASCULAR RISK REDUCTION | April 2022 | April 2025 | Abandon | 36 | 0 | 1 | No | No |
| 17725462 | ISOLATION, IDENTIFICATION AND APPLICATION OF STREPTOCOCCUS SP. 121 | April 2022 | June 2023 | Abandon | 13 | 2 | 0 | No | No |
| 17431346 | LIQUID FERTILIZER PRODUCTION METHOD AND HIGHQUALITY LIQUID FERTILIZER BASED ON L F Q C AND CHLORELLA MICROBIOLOGICAL FERTILIZER MANUFACTURE METHOD | April 2022 | October 2025 | Abandon | 50 | 2 | 1 | No | No |
| 17769268 | COMPOSITIONS COMPRISING HYALURONIDASE AND/OR COLLAGENASE AND/OR 4-METHYLUMBELLIFERONE (4-MU) AND METHODS OF TREATMENT USING SAME | April 2022 | July 2025 | Abandon | 39 | 1 | 0 | No | No |
| 17595616 | USE OF ENZYME THAT CLEAVES BOTH ALPHA- AND BETA-1,4-GLYCOSIDIC BONDS | April 2022 | June 2025 | Allow | 42 | 1 | 0 | No | No |
| 17709527 | Strain of Lactobacillus crispatus Capable of Preventing and/or Treating Helicobacter pylori Infection | March 2022 | February 2025 | Allow | 34 | 2 | 0 | No | No |
| 17698490 | VIABLE LYOPHILIZED COMPOSITIONS DERIVED FROM HUMAN TISSUES AND METHODS OF MAKING THE SAME | March 2022 | December 2025 | Abandon | 45 | 4 | 1 | No | No |
| 17642391 | HYDROGEL COMPOSITIONS COMPRISING PROTIST CELLS | March 2022 | February 2025 | Abandon | 35 | 0 | 1 | No | No |
| 17692414 | USE OF LACTOBACILLUS PARACASEI GM-080 FOR MODULATING IMMUNE FUNCTION | March 2022 | February 2026 | Allow | 47 | 3 | 1 | Yes | No |
| 17691325 | PROCESS FOR THE CONVERSION OF LIGNOCELLULOSE MATERIAL INTO AN ORGANIC ACID | March 2022 | January 2024 | Allow | 23 | 1 | 0 | No | No |
| 17685908 | BIFIDOBACTERIUM LACTIS BL-99 AND APPLICATION THEREOF | March 2022 | November 2023 | Allow | 20 | 1 | 1 | No | No |
| 17685974 | BIFIDOBACTERIUM LACTIS BL-99 AND APPLICATION THEREOF | March 2022 | November 2023 | Allow | 20 | 1 | 1 | No | No |
| 17674834 | PREBIOTIC COMPOSITION AND METHODS FOR USING THE SAME | February 2022 | August 2023 | Allow | 18 | 1 | 1 | No | No |
| 17673460 | LACTOBACILLUS PARACASEI STRAIN AND USE THEREOF | February 2022 | March 2024 | Allow | 25 | 2 | 1 | No | No |
| 17632865 | MEDICAMENT FOR TREATING STROKE CAUSED BY DEEP FUNGAL INFECTIONS | February 2022 | January 2025 | Abandon | 35 | 1 | 0 | No | No |
| 17632497 | ENGINEERED BIOSYNTHETIC PATHWAYS FOR PRODUCTION OF 3-AMINO-4-HYDROXYBENZOIC ACID BY FERMENTATION | February 2022 | July 2025 | Abandon | 41 | 1 | 0 | No | No |
| 17630963 | COMPOSITION FOR IMPROVING SKIN CONDITION | January 2022 | December 2024 | Abandon | 35 | 1 | 0 | Yes | No |
| 17630018 | NUTRITIVE COMPOSITIONS WITH SECRETED IgA, MILK FAT GLOBULE MEMBRANE COMPONENTS AND/OR BIFIDOBACTERIUM | January 2022 | December 2024 | Abandon | 35 | 0 | 1 | No | No |
| 17626965 | TRANSGENIC BACTERIA AND METHODS OF USING SAME | January 2022 | May 2025 | Abandon | 40 | 1 | 0 | No | No |
| 17571387 | BLOOD GLUCOSE CONTROL AND ANTI-OBESITY PROBIOTICS COMPOSITIONS IN A SPECIFIC SELECTION AND RATIO | January 2022 | October 2023 | Abandon | 21 | 1 | 1 | No | No |
| 17624377 | METERED DOSING COMPOSITIONS AND METHODS OF USE OF PSYCHEDELIC COMPOUNDS | January 2022 | February 2025 | Abandon | 38 | 0 | 1 | No | No |
| 17623947 | Bifidobacterium Longum Subsp. Infantis CCFM687 and Fermented Food and Application Thereof | December 2021 | January 2025 | Abandon | 37 | 1 | 0 | No | No |
| 17597177 | ANTIPROLIFERATIVE EFFECT OF AGAROPHYTON CHILENSIS EXTRACT IN PROSTATE CANCER | December 2021 | January 2026 | Allow | 49 | 2 | 1 | No | No |
| 17623233 | Integrated Biomarker System for Evaluating Risks of Impaired Fasting Glucose (IFG) and Type 2 Diabetes Mellitus (T2DM) | December 2021 | May 2025 | Abandon | 41 | 1 | 0 | No | No |
| 17547361 | PROBIOTIC SPORTS NUTRITION COMPOSITIONS | December 2021 | October 2025 | Abandon | 46 | 4 | 0 | No | No |
| 17542040 | Algae Beads | December 2021 | February 2025 | Abandon | 38 | 3 | 1 | Yes | No |
| 17534361 | COMPOSITIONS AND METHODS FOR INHIBITION OF PATHOGENIC BACTERIAL GROWTH | November 2021 | August 2024 | Abandon | 33 | 1 | 1 | No | No |
| 17529117 | SURGICAL RECOVERY SUPPLEMENT | November 2021 | October 2023 | Abandon | 23 | 1 | 1 | No | No |
| 17525328 | AIRWAY MEDICAMENTS | November 2021 | February 2025 | Allow | 39 | 6 | 0 | No | No |
| 17279293 | IMMUNOSTIMULATOR AND METHOD FOR PREVENTING INFECTION | November 2021 | August 2025 | Abandon | 53 | 2 | 1 | No | No |
| 17517422 | PERFUSION BIOREACTOR AND RELATED METHODS OF USE | November 2021 | December 2023 | Allow | 25 | 2 | 0 | Yes | No |
| 17514670 | EXTERNAL COMPOSITION FOR WOUND HEALING CONTAINING LACTOBACILLUS FERMENTATION PRODUCT AND METHOD FOR PROMOTING WOUND HEALING USING THE SAME | October 2021 | July 2023 | Allow | 21 | 1 | 1 | No | No |
| 17498188 | METHODS FOR TREATING CANCER BY ADJUSTING SELECTED METABOLITES | October 2021 | January 2025 | Abandon | 40 | 0 | 1 | No | No |
| 17494958 | NON-INVASIVE SAMPLING OF INNER-COLONIC MICROBIOME | October 2021 | December 2024 | Abandon | 38 | 0 | 1 | No | No |
| 17598785 | DIRECT DETECTION METHOD FOR TICK-BORNE INFECTIONS AND A CELL TECHNOLOGY MEDIUM FOR THE METHOD | September 2021 | November 2024 | Allow | 37 | 3 | 1 | Yes | No |
| 17440747 | STRAINS OF LACTOBACILLUS DELBRUECKII WHICH INHIBIT PORPHYROMONAS GINGIVALIS | September 2021 | June 2023 | Allow | 21 | 2 | 1 | No | No |
| 17472979 | ENHANCED PRODUCTION OF RHAMNOLIPIDS USING AT LEAST TWO CARBON SOURCES | September 2021 | March 2024 | Allow | 30 | 2 | 1 | No | No |
| 17473758 | COMPOSITIONS AND METHODS FOR PROVIDING PLANTS WITH TOLERANCE TO HEAT STRESS | September 2021 | June 2024 | Abandon | 33 | 1 | 1 | No | No |
| 17465124 | BOTULINUM TOXIN ADMINISTRATION FOR TREATMENT OF NEUROGENIC DETRUSOR OVERACTIVITY ASSOCIATED URINARY INCONTINENCE | September 2021 | November 2023 | Abandon | 26 | 1 | 0 | No | No |
| 17411812 | PROCESS FOR BACTERIALLY DEVULCANIZING SULPHUR-VULCANIZED RUBBER PARTICLES | August 2021 | August 2023 | Abandon | 24 | 1 | 0 | No | No |
| 17392346 | MEDIUM FOR THE SPECIFIC DETECTION OF RESISTANT MICROORGANISMS | August 2021 | April 2024 | Abandon | 32 | 2 | 1 | No | No |
| 17370849 | METHOD OF CULTURING HAEMATOCOCCUS SPECIES FOR MANUFACTURING OF ASTAXANTHIN | July 2021 | January 2025 | Allow | 42 | 3 | 0 | No | No |
| 17368601 | Microbial Biomass-Based Feed Products | July 2021 | February 2026 | Abandon | 55 | 3 | 1 | No | No |
| 17365619 | Process For Accelerating, Increasing, and Stabilizing Production of Biogas with a High Methane Content in Systems For Anaerobic Biodigestion of Organic Wastes | July 2021 | March 2023 | Allow | 20 | 1 | 0 | No | No |
| 17420177 | Supplemented Serum-Containing Culture Medium for Enhanced Arpe-19 Growth and Human Cytomegalovirus Vaccine Production | July 2021 | November 2025 | Abandon | 53 | 2 | 1 | No | No |
| 17296308 | USE OF PROBIOTIC YEAST CELLS PRODUCING RECOMBINANT PARATHORMONE FOR THERAPEUTIC PURPOSES | May 2021 | October 2024 | Allow | 41 | 3 | 0 | Yes | No |
| 17324698 | SKIN CARE APPLICATIONS OF EXTRACELLULAR METABOLITES FROM BACILLUS COAGULANS | May 2021 | October 2023 | Allow | 29 | 2 | 0 | Yes | No |
| 17245833 | DRIED BACTERIAL CELL POWDER CONTAINING A CAROTENOID AND METHOD FOR PRODUCING THE SAME | April 2021 | October 2023 | Abandon | 30 | 1 | 0 | No | No |
| 17288383 | SPOREFORMING PROBIOTIC STRAINS, METHODS AND USES THEREOF | April 2021 | November 2022 | Allow | 18 | 2 | 0 | No | No |
| 17287719 | Probiotic Supplement For Metabolic Health | April 2021 | December 2023 | Allow | 32 | 2 | 1 | No | No |
| 17284985 | Personalized System for Restoring the Gastrointestinal Tract Microbiome | April 2021 | June 2024 | Abandon | 38 | 4 | 0 | No | No |
| 17223340 | METHOD OF REDUCING CONCENTRATIONS OF ONE OR MORE OF N2O and NO IN MEDIUM | April 2021 | September 2024 | Abandon | 41 | 4 | 0 | No | No |
| 17217185 | LACTOBACILLUS CASEI FOR TREATING OBESITY AND ASSOCIATED METABOLIC DISORDERS | March 2021 | July 2022 | Allow | 15 | 1 | 0 | No | No |
| 17217305 | BIFIDOBACTERIUM LACTIS BL-99 AND APPLICATION THEREOF | March 2021 | December 2021 | Allow | 8 | 1 | 1 | No | No |
| 17280733 | ADDITIVE FOR MEDIUM FOR PROMOTING PRODUCTION OF PARACRINE FACTOR | March 2021 | September 2024 | Abandon | 42 | 0 | 1 | No | No |
| 17210078 | MICROBIAL COMPOSITIONS AND METHODS OF USE | March 2021 | September 2023 | Abandon | 30 | 0 | 1 | No | No |
| 17200585 | METHODS OF PREVENTING AND TREATING COVID-19 INFECTION WITH PROBIOTICS | March 2021 | March 2023 | Allow | 24 | 3 | 1 | Yes | No |
| 16981417 | OBESITY TREATMENT USING PROBIOTICS, COMPOSITION FOR REDUCING BODY FAT, AND COMPOSITION FOR REDUCING WAIST CIRCUMFERENCE | March 2021 | June 2024 | Allow | 45 | 4 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner AFREMOVA, VERA.
With a 50.0% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 20.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner AFREMOVA, VERA works in Art Unit 1653 and has examined 715 patent applications in our dataset. With an allowance rate of 48.8%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 37 months.
Examiner AFREMOVA, VERA's allowance rate of 48.8% places them in the 11% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by AFREMOVA, VERA receive 2.48 office actions before reaching final disposition. This places the examiner in the 72% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by AFREMOVA, VERA is 37 months. This places the examiner in the 31% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +34.5% benefit to allowance rate for applications examined by AFREMOVA, VERA. This interview benefit is in the 82% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 17.5% of applications are subsequently allowed. This success rate is in the 16% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 35.9% of cases where such amendments are filed. This entry rate is in the 54% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 50.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 42% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.
This examiner withdraws rejections or reopens prosecution in 64.3% of appeals filed. This is in the 44% percentile among all examiners. Of these withdrawals, 55.6% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.
When applicants file petitions regarding this examiner's actions, 65.2% are granted (fully or in part). This grant rate is in the 70% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 0.4% of allowed cases (in the 59% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 5.2% of allowed cases (in the 81% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.